Vertex (VRTX) Stock Still Looks Like A Bargain On Its 181% Run
Vertex Pharmaceuticals has produced a strong long term return, yet the current share price still sits below one widely used intrinsic value estimate. For investors, the interest lies in the gap between a Discounted Cash Flow estimate that screens the stock as undervalued and market multiples that look broadly in line.
- Over the past 5 years, Vertex Pharmaceuticals has returned 180.7%, which puts long term holders in a comfortable position even if near term swings feel noisy.
- Future cash flow from its existing and potential therapies can support the current valuation, while any setback in drug development or pricing pressure may weigh heavily on longer range assumptions.
- The broader valuation checks point to a mixed picture rather than a clear bargain or clear overvaluation, with a value score of 4 out of 6 suggesting some signals are supportive while others are more neutral.
The issue now is whether the discount to the intrinsic value estimate offers enough compensation for the risks embedded in Vertex Pharmaceuticals cash flow outlook.
Scan other drug makers that pair strong balance sheets with measured valuations by running through solid balance sheet and fundamentals stocks screener (24 results) as a comparison set beside Vertex Pharmaceuticals.
Is Vertex Pharmaceuticals a Bargain on Cash Flow?
The Discounted Cash Flow (DCF) model values a business based on the cash it can return to shareholders over time. For Vertex Pharmaceuticals, the latest twelve month free cash flow sits at about US$3.8b, and the model assumes these cash flows keep growing rather than shrinking. On those projections, the DCF points to an estimated intrinsic value of about $688 per share.
Set against the current market price, that outcome implies Vertex Pharmaceuticals trades at roughly a 23.1% discount to this intrinsic value estimate. The gap suggests investors are treating the future cash generation from the drug portfolio more cautiously than the DCF assumptions do, especially across the later years of the forecast.
On this cash flow view, Vertex Pharmaceuticals stock appears undervalued relative to the DCF estimate.
Our Discounted Cash Flow (DCF) analysis suggests Vertex Pharmaceuticals is undervalued by 23.1%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.
Does Vertex Pharmaceuticals Look Fairly Valued on Earnings?
P/E is a useful lens for Vertex Pharmaceuticals because earnings already reflect mature cash generation from its drug portfolio. On this metric, the stock trades on a P/E of about 30.4x. That sits below a peer average of roughly 37.7x for similar companies, yet above the wider biotech sector, which sits closer to 16.6x.
The fair P/E ratio for Vertex Pharmaceuticals, based on its profile, screens around 33.6x. That is only modestly above where the shares change hands today, which indicates the current price already reflects much of the earnings power implied by this framework without moving far beyond it.
On the P/E view, Vertex Pharmaceuticals appears priced roughly in line with what this model describes as a fair valuation.
See what the numbers say about this price — find out in our valuation breakdown.
The Vertex Pharmaceuticals Narrative: What Would Justify Today's Price?
Vertex Pharmaceuticals' valuation gap only really makes sense once the underlying story is clear. This is where Simply Wall St Narratives come in as a structured set of what-if scenarios that spell out which growth, margin and earnings paths would need to play out for the stock to be worth materially more or materially less than today’s price on the Community page. Each scenario links a fair value estimate to a specific mix of potential catalysts and risks for Vertex Pharmaceuticals, so you can track over time which storyline is actually taking shape in the real world.
Community views on Vertex Pharmaceuticals pull in opposite directions, with one camp focused on new growth pillars and the other on rising execution risk.
Bull case: 5% undervalued
"Vertex's pipeline diversification, including programs in pain, kidney, and type 1 diabetes, leverages global advances in genomic and gene-editing technologies..."
Read the full Bull Case to see why Vertex Pharmaceuticals could be undervalued
Bear case: 25% overvalued
"Intensifying regulatory pressures and high treatment costs threaten Vertex's pricing power and market expansion, leading to margin compression and limited revenue growth..."
Read the full Bear Case to see why Vertex Pharmaceuticals could be overvalued
Do you think there's more to the story for Vertex Pharmaceuticals? Head over to our Community to see what others are saying!
The Bottom Line
Vertex Pharmaceuticals screens as undervalued on the Discounted Cash Flow (DCF) estimate, with the intrinsic value sitting meaningfully above the current share price. Market multiples point to something closer to about right, which tempers how far that DCF gap can be taken as a clear signal. The split comes down to how much faith you place in the durability and expansion of future cash flows from the drug portfolio. That same assumption is what separates the bull view of a mispriced compounder from the bear view that the discount is simply compensation for execution and regulatory risk.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com